Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Upcoming SlideShare
animal toxicity studies
Download to read offline and view in fullscreen.



Download to read offline

Animal toxicology studies

Download to read offline

Related Books

Free with a 30 day trial from Scribd

See all

Related Audiobooks

Free with a 30 day trial from Scribd

See all

Animal toxicology studies

  2. 2. <ul><li>Benefit –risk ratio can be calculated </li></ul><ul><li>Prediction of therapeutic index </li></ul><ul><li>Therapeutic index= Maximum tolerated dose </li></ul><ul><li> Minimum curative dose </li></ul><ul><li>Smaller ratio, better safety of the drug </li></ul>
  3. 3. <ul><li>Pharmacological effects are same in man as in animals </li></ul><ul><li>Toxic effect in species will predict adverse effects in man </li></ul><ul><li>Giving high doses in animals improves predictability to man </li></ul><ul><li>Risk assessment can be made by comparison of toxic doses in test species with predicted therapeutic dose in man </li></ul>
  4. 4. PHASES OF DRUG DEVELOPMENT (ANIMAL MAN) PHASE III PHASE IV PHASE I PHASE I PRECLINICAL PHASE II Product Approval (NDA/MAA) Patient studies Entry to man (IND / CTA) None Healthy subjects Safety and tolerability Genetic toxicity (in vivo) Repeat dose toxicity testing + Bioanalysis / Toxicokinetics Drug Metabolism Reproductive Toxicity Testing (teratogenicity) Patients Small scale efficacy studies Patients Large scale multicentre studies Chronic (long term) toxicity testing + Bioanalysis / Toxicokinetics Reproductive Toxicity Testing (fertility and pre/post natal) Carcinogenicity studies Drug Metabolism Patients Large scale post-marketing studies As required Genetic toxicity (in vitro) Single / repeat dose toxicity studies + Bioanalysis / Toxicokinetics Safety Pharmacology Drug Metabolism Lead candidate Identified Clinical Non-clinical MOLECULE
  5. 5. <ul><li>Studies should comply with GLP </li></ul><ul><li>Performed by trained and qualified staff </li></ul><ul><li>Use of standardized and calibrated equipment </li></ul><ul><li>SOP’s followed in laboratory tasks </li></ul><ul><li>All documents should be preserved for minimum 5 years after marketing of the drug </li></ul>
  6. 6. TOXICOKINETIC STUDIES <ul><li>Generation of Pharmacokinetic data to access systemic exposure achieved in animals </li></ul><ul><li>Relation to dose level and the time course of toxicity study </li></ul><ul><li>To support choice of species & Treatment regimen </li></ul><ul><li>Design on clinical studies accordingly </li></ul>
  7. 7. <ul><li>Pharmacodynamic responses </li></ul><ul><li>Pharmacokinetic profile </li></ul><ul><li>Species, sex, age of experimental animals </li></ul><ul><li>Susceptibility, sensitivity and reproducibility of test system </li></ul><ul><li>In vitro: Isolated organs, tissues cell-cultures </li></ul><ul><li>Mechanism of effect in vivo </li></ul>
  8. 8. <ul><li>Systemic toxicology studies </li></ul><ul><li>Single dose studies Repeated dose studies </li></ul><ul><li>Reproductive toxicology studies </li></ul><ul><li>Male fertility Female reproduction & Developmental </li></ul><ul><li>studies </li></ul><ul><li>Local toxicity studies </li></ul><ul><li>Hypersensitivity studies </li></ul><ul><li>Genotoxicity studies </li></ul><ul><li>Carcinogenicity studies </li></ul>
  9. 9. <ul><li>Preliminary Definitive </li></ul><ul><li>Maximum Non Lethal dose </li></ul><ul><li>(MNLD) determined </li></ul><ul><li>MTD and MLD determined </li></ul><ul><li>Evaluate effects </li></ul><ul><li>Target organ of toxicity may be determined </li></ul><ul><li>SINGLE DOSE STUDIES/ ACUTE TOXICITY </li></ul>
  10. 10. <ul><li>METHOD </li></ul><ul><li>Single dose tested in 2 rodent species </li></ul><ul><li>2 routes of administration </li></ul><ul><li>Oral dosing of 2g/kg or 10 times of normal human dose </li></ul><ul><li>Observation for 14 days after dosing </li></ul><ul><li>MNLD established </li></ul><ul><li>Symptoms , signs reported </li></ul><ul><li>Microscopic and Macroscopic evaluation </li></ul>
  11. 11. <ul><li>METHOD </li></ul><ul><li>Group of 20 animals of either sex dosed at MNLD </li></ul><ul><li>5 animals of each sex are observed for 48 hr and conduct autopsy for early pathological changes </li></ul><ul><li>Remaining 5 of each sex are observed for 14 days </li></ul><ul><li>MTD and MLD established </li></ul><ul><li>Signs of intoxication or recovery, changes in body weight, pathological changes </li></ul><ul><li>Complete macroscopic and microscopic examination </li></ul><ul><li>Target organs can be identified </li></ul>
  12. 12. <ul><li>Two mammalian species(one should be non-rodent) </li></ul><ul><li>Long duration studies (30-180 days) </li></ul><ul><li>Dose is dependent on dose-escalating studies </li></ul><ul><li>Drug administered by clinical route </li></ul><ul><li>Parameters monitored and recorded are: </li></ul><ul><ul><li>Behavioral </li></ul></ul><ul><ul><li>Physiological </li></ul></ul><ul><ul><li>Biochemical </li></ul></ul><ul><ul><li>Microscopic observations </li></ul></ul>b) REPEATED DOSE STUDIES/SUB-ACUTE OR CHRONIC TOXICITY
  13. 13. <ul><li>a) MALE FERTILITY </li></ul><ul><li>METHOD </li></ul><ul><li>One rodent species(rat) </li></ul><ul><li>3 dose groups taken </li></ul><ul><li>(each with 6 adult males), </li></ul><ul><li>1 control </li></ul><ul><li>Drug treatment by clinical route for 28-72 days </li></ul>
  14. 14. <ul><li>Mated with females in 1:2 ratio </li></ul><ul><li>Females getting pregnant should be examined </li></ul><ul><li>After 13 days of gestation </li></ul><ul><li>All male animals sacrificed </li></ul><ul><li>Weights of testis, epididymus recorded & examined for their histology </li></ul><ul><li>Sperms examined for motility & morphology </li></ul>
  15. 15. <ul><li>Segment I </li></ul>Fertility and general reproductive performance study Segment II Teratogenicity Segment III Peri and post-natal study Fertility and early embryonic development (rat) Embryo- foetal development (rat & rabbit) Post natal development (rat) (post natal survival of offspring), growth parameters, vital senses, behavioral effects <ul><li>b) FEMALE FETILITY </li></ul><ul><li>Drug administered to both males (28days) and females (14 days) before mating </li></ul>Implantation Embryogenesis
  16. 16. <ul><li>Required when drug is administered by special route (other than oral) in humans </li></ul><ul><li>Study design: </li></ul><ul><ul><li>2 species along with control used </li></ul></ul><ul><ul><li>Dose dependent on dose escalating studies </li></ul></ul><ul><ul><li>3 dose levels </li></ul></ul>
  17. 17. <ul><li>Dermal toxicity studies </li></ul><ul><li>Dermal photo-toxicity studies </li></ul><ul><li>Vaginal toxicity studies </li></ul><ul><li>Rectal tolerance studies </li></ul><ul><li>Rats & Rabbit </li></ul><ul><li>Local signs (erythema, oedema), histological examination </li></ul><ul><li>Guinea pig </li></ul><ul><li>Used in treatment of leucoderma </li></ul><ul><li>Examination of erythema & oedema formation </li></ul><ul><li>Rabbit or Dog </li></ul><ul><li>Observation of swelling, histopathology of vaginal wall </li></ul><ul><li>Rabbit or Dog </li></ul><ul><li>Signs of pain, blood or mucous, histology examination of rectal mucosa </li></ul>
  18. 18. <ul><li>Ocular toxicity studies </li></ul><ul><li>Parenteral drugs </li></ul><ul><li>Inhalation toxicity studies </li></ul><ul><li>Albino Rabbit </li></ul><ul><li>Changes in cornea ,Iris & aqueous humor, histological examination of eye </li></ul><ul><li>For intravenous/ intramuscular/ subcutaneous/ intra-dermal injection </li></ul><ul><li>Sites of injection examined grossly and microscopically </li></ul><ul><li>One rodent and non rodent species </li></ul><ul><li>Acute , sub-acute and chronic studies performed </li></ul><ul><li>Observation of respiratory rate </li></ul><ul><li>Histological examination of respiratory passages, lung tissue </li></ul>
  19. 19. <ul><li>Guinea Pig Maximization test </li></ul><ul><li>Local lymph node assay </li></ul><ul><li>Determination of Maximum non irritant or minimum irritant dose </li></ul><ul><li>Evaluation of Erythema and oedema </li></ul><ul><li>Mice of one sex(either male or female) </li></ul><ul><li>Drug treatment given on ear skin </li></ul><ul><li>Auricular lymph node dissection after 5 days </li></ul><ul><li>Increase in 3h-thymidine used for evaluation </li></ul>
  20. 20. <ul><li>To detect early tumorigenic effects in cases of chronic illness </li></ul><ul><li>In vitro tests: </li></ul><ul><ul><li>Test for gene mutation in Bacteria </li></ul></ul><ul><ul><li>Cytogenetic evaluation of chromosomal damage in mammalian cells </li></ul></ul><ul><ul><li>E.g .; Ames’s Salmonella Assay detects increased number of aberrations in metaphase chromosomes </li></ul></ul><ul><ul><li>DNA strand breaks, DNA repair or recombination, Measurements of DNA adducts </li></ul></ul><ul><li>In vivo tests: </li></ul><ul><ul><li>Chromosome damage in rodent hematopoietic cells </li></ul></ul><ul><li>E.g .; Micronucleus Assay </li></ul>
  21. 21. <ul><li>Life-time Bioassays </li></ul><ul><li>Carcinogenicity studies are performed on: </li></ul><ul><li>Drug used for >6 months or frequent intermittent use for chronic diseases </li></ul><ul><li>Chemical structure of drug indicates carcinogenic potential </li></ul><ul><li>Therapeutic class of drugs which have produced positive carcinogenicity </li></ul>
  22. 22. <ul><li>Group sizes of 50 animals/sex at each of 3 dose levels </li></ul><ul><li>Control group is of double size </li></ul><ul><li>Record for onset of tumor development </li></ul><ul><li>Usually carried out for 24 months in rats and 18 months in mice (life span studies ) </li></ul>CONDUCT OF STUDY
  23. 23. EVALUATION OF RESULT <ul><li>Incidence of cancers in control and test </li></ul><ul><li>Trend towards increasing incidence with increasing doses </li></ul><ul><li>Number of animals with single/multiple tumors </li></ul><ul><li>Macroscopic changes observed by autopsy </li></ul><ul><li>Histopathology of organs and tissues </li></ul>
  • RabiatuBawa

    Sep. 18, 2021
  • MidhunMithra1

    Sep. 15, 2021
  • KowsalyaKowsalya9

    Sep. 8, 2021
  • NavyasriBandaripalli

    Jul. 18, 2021
  • NeerajaGujarathi

    Jul. 12, 2021
  • KShabna1

    Jul. 9, 2021
  • shanthimukundan

    Jun. 12, 2021
  • PreethiPreethi44

    Jun. 9, 2021
  • TushantDarvesh

    Mar. 11, 2021
  • NicoletteNik

    Dec. 8, 2020
  • JagadeeshJagguBhai

    Nov. 19, 2020
  • AdapakaSarala

    Sep. 30, 2020
  • AshithaGeorge2

    Sep. 23, 2020
  • AjaTajNazer

    Sep. 10, 2020
  • PragatiPandey13

    Jun. 20, 2020
  • sudeshnakopparapu

    Jun. 19, 2020
  • creativedesignucan

    May. 27, 2020
  • SantoshDrSantoshAyu

    May. 2, 2020
  • KalpanaKandpal

    Apr. 28, 2020
  • ShruthiMangalore

    Apr. 14, 2020


Total views


On Slideshare


From embeds


Number of embeds